DEFINITION AND DESCRIPTION OF DIABETES MELLITUSdDiabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of different organs, especially the eyes, kidneys, nerves, heart, and blood vessels. Several pathogenic processes are involved in the development of diabetes. These range from autoimmune destruction of the b-cells of the pancreas with consequent insulin deficiency to abnormalities that result in resistance to insulin action. The basis of the abnormalities in carbohydrate, fat, and protein metabolism in diabetes is deficient action of insulin on target tissues. Deficient insulin action results from inadequate insulin secretion and/or diminished tissue responses to insulin at one or more points in the complex pathways of hormone action. Impairment of insulin secretion and defects in insulin action frequently coexist in the same patient, and it is often unclear which abnormality, if either alone, is the primary cause of the hyperglycemia. Symptoms ofmarked hyperglycemia includepolyuria,polydipsia,weight loss,sometimes with polyphagia, and blurred vision. Impairment of growth and susceptibility to certain infections may also accompany chronic hyperglycemia. Acute, life-threatening consequences of uncontrolled diabetes are hyperglycemia with ketoacidosis or the nonketotic hyperosmolar syndrome. Long-term complications of diabetes include retinopathy with potential loss of vision; nephropathy leading to renal failure; peripheral neuropathy with risk of foot ulcers, amputations, and Charcot joints; and autonomic neuropathy causing gastrointestinal, genitourinary, and cardiovascular symptoms and sexual dysfunction. Patients with diabetes have an increased incidence of atherosclerotic cardiovascular, peripheral arterial, and cerebrovascular disease. Hypertension and abnormalities of lipoprotein metabolism are often found in people with diabetes. The vast majority of cases of diabetes fall into two broad etiopathogenetic categories (discussed in greater detail below). In one category, type 1 diabetes, the cause is an absolute deficiency of insulin secretion. Individuals at increased risk of developing this type of diabetes can often be identified by serological evidence of an autoimmune pathologic process occurring in the pancreatic islets and by genetic markers. In the other, much more prevalent category, type 2 diabetes, the cause is a combination of resistance to insulin action and an inadequate compensatory insulin secretory response. In the latter category, a degree of hyperglycemia sufficient to cause pathologic and functional changes in various target tissues, but without clinical symptoms, may be present for a long period of time before diabetes is detected. During this asymptomatic period, it is possible to demonstrate an abnormality in carbohydrate metabolism by measurement of plasma glucose in the fasting state or after a challenge with an oral glucose load or by A1C. The degree of hyperglycemia (if any) may change over time, depending on the extent of the underlying disease process (Fig. 1). A disease process may be present but may not have progressed far enough to cause hyperglycemia. The same disease process can cause impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) without fulfilling the criteria for the diagnosis of diabetes. In some individuals with diabetes, adequate glycemic control can be achieved with weight reduction, exercise, and/or oral glucose-lowering agents. These individuals therefore do not require insulin. Other individuals who have some residual insulin secretion but require exogenous insulin for adequate glycemic control can survive without it. Individuals with extensive b-cell destruction and therefore no residual insulin secretion require insulin for survival. The severity of the metabolic abnormality can progress, regress, or stay the same. Thus, the degree of hyperglycemia reflects the severity of the underlying metabolic process and its treatment more than the nature of the process itself.
[1]
D. Williamson,et al.
Identifying adults at high risk for diabetes and cardiovascular disease using hemoglobin A1c National Health and Nutrition Examination Survey 2005-2006.
,
2011,
American journal of preventive medicine.
[2]
D. Williamson,et al.
A1C Level and Future Risk of Diabetes: A Systematic Review
,
2010,
Diabetes Care.
[3]
A. Thanopoulou,et al.
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.
,
2010,
The New England journal of medicine.
[4]
Bengt Persson,et al.
International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy
,
2010,
Diabetes Care.
[5]
Dwight J Rouse,et al.
A multicenter, randomized trial of treatment for mild gestational diabetes.
,
2009,
The New England journal of medicine.
[6]
Sigridur Sia Jonsdottir,et al.
Hyperglycemia and Adverse Pregnancy Outcomes
,
2009
.
[7]
J. Shaw,et al.
International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes
,
2009,
Diabetes Care.
[8]
Hiroshi Kambe,et al.
Combined Measurement of Fasting Plasma Glucose and A1C Is Effective for the Prediction of Type 2 Diabetes
,
2009,
Diabetes Care.
[9]
P. Ridker,et al.
Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women.
,
2007,
The American journal of medicine.
[10]
K. Ohe,et al.
Hemoglobin A1c (HbA1c) predicts future drug treatment for diabetes mellitus: a follow-up study using routine clinical data in a Japanese university hospital.
,
2007,
Translational research : the journal of laboratory and clinical medicine.
[11]
T. Dudley,et al.
Utility of hemoglobin A1c in predicting diabetes risk
,
2004,
Journal of General Internal Medicine.
[12]
B. Balkau,et al.
Use of HbA1c in Predicting Progression to Diabetes in French Men and Women
,
2006,
Diabetes Care.
[13]
M. Engelgau,et al.
Changes in incidence of diabetes in U.S. adults, 1997-2003.
,
2006,
American journal of preventive medicine.
[14]
J. Hiller,et al.
Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.
,
2005,
The New England journal of medicine.
[15]
P. Raskin,et al.
Report of the expert committee on the diagnosis and classification of diabetes mellitus.
,
1999,
Diabetes care.
[16]
S. Fowler,et al.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
,
2002
.
[17]
M. Fantone,et al.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
,
1997,
Diabetes Care.
[18]
D. Coustan,et al.
Criteria for screening tests for gestational diabetes.
,
1982,
American journal of obstetrics and gynecology.
[19]
C. Mahan,et al.
CRITERIA FOR THE ORAL GLUCOSE TOLERANCE TEST IN PREGNANCY.
,
1964,
Diabetes.